GeoVax Secures Patent for Innovative Malaria Vaccine Design
GeoVax Labs, Inc. has been granted a U.S. patent for a novel vaccine construct aimed at preventing malaria, marking a significant step forward in the fight against the disease and other infectious threats.
GeoVax Labs, Inc. (Nasdaq: GOVX) has announced the issuance of U.S. Patent No. 12,329,808, covering a novel vaccine construct designed to prevent malaria infection. This patent underscores the company's innovative approach to vaccine development, utilizing a recombinant Modified Vaccinia Ankara (MVA) viral vector to express immunogenic proteins from Plasmodium falciparum, the parasite responsible for malaria. The technology enables the expression of virus-like particles (VLPs) that enhance vaccine potency by inducing both humoral and T-cell responses.
David Dodd, GeoVax President and CEO, emphasized the importance of this patent in advancing vaccines for globally persistent and emerging pathogens. The company's multi-antigenic platform strategy, exemplified by this patent, is pivotal for pandemic preparedness and global health security. GeoVax's intellectual property portfolio now includes over 135 granted or pending patent applications across 23 distinct families, reinforcing its position in oncology, infectious diseases, and biodefense.
Malaria continues to pose a significant health threat worldwide, with over 600,000 deaths annually, mostly in sub-Saharan Africa. GeoVax's MVA-based platform offers a promising solution for inducing durable immunity against malaria and other infectious diseases. This development represents a critical advancement in the ongoing effort to combat malaria and underscores the potential of GeoVax's technology to address some of the world's most pressing health challenges.